Civilian penetrating traumatic brain injury in South-East Norway Authors: Mads Aarhus, Dag Ferner Netteland, Cathrine Tverdal, Vidar Stenset, Pål Rønning, Eirik Helseth Published: 2026 ABSTRACT BackgroundCivilian penetrating traumatic brain injury (cpTBI) is a rare entity associated with severe and often devastating consequences. Guidelines recommend CT angiography (CTA), prophylactic antibiotics (AB) and antiseizure medication (ASM), early surgical revision with dural closure whenever feasible, and intracranial pressure (ICP)-guided therapy. The study aimed to investigate guideline compliance, as well as outcome after cpTBI for patients admitted to Oslo University Hospital (OUH).MethodsWe identified and included cpTBI patients admitted to OUH between 2015 and 2023 through the Oslo TBI Registry – Neurosurgery. Guideline adherence was assessed and variables associated with 30-day mortality and Glasgow Outcome Scale (GOS) were examined using standard uni- and multivariable techniques.ResultsThe incidence of cpTBI was 1.9/1.000.000 with a 30-day mortality rate of 42.3%. Among the survivors, 70% achieved a favourable outcome (GOS 4 and 5) at 6 months. CTA was obtained at an acceptable rate (81%) in concordance with guidelines, but the guideline compliance for AB (12%) and ASM (29%) was substantially lower-than-expected. Surgery started within 12 h after injury in 58%, and ICP was monitored in 53.5% of patients with GCS < 9.ConclusionsDespite high mortality in cpTBI, most survivors achieved favourable outcome. We found a lower-than-expected guideline compliance for prophylactic AB and ASM, ICP monitoring, and surgical revision within 12 h. Thus, we identified several key factors that can improve cpTBI treatment at our institution. For patients considered potential survivors, management should be aggressive and aligned with established TBI treatment principles, including early vascular imaging with CTA, prompt wound debridement with dural closure, and prophylactic administration of AB and ASM. Background Civilian penetrating traumatic brain injury (cpTBI) is a rare entity often associated with devastating consequences. The penetrating object violates the natural barriers contaminating the wound tract, potentially causing injury to the dura, brain tissue, cranial nerves, intracerebral vessels and ventricular system. Owing to its low incidence, standardized treatment protocols are essential to minimize unwarranted variation in clinical management. Current management of cpTBI is grounded in Advanced Trauma Life Support (ATLS) principles and the 2001 Brain Trauma Foundation Guidelines, with early neuroimaging, typically non-contrast cranial CT combined with CT angiography, serving as a cornerstone of initial assessment [1, 2]. Prompt surgical debridement and dural closure are recommended to mitigate infection risk and prevent secondary injury [2, 3]. Although no dedicated consensus exists for intracranial pressure (ICP) management specific to cpTBI, it is generally considered appropriate to follow the Brain Trauma Foundation (BTF) guidelines for severe traumatic brain injury (TBI). This includes ICP monitoring in patients presenting with a Glasgow Coma Scale (GCS) score below 9 [4, 5]. Furthermore, it is recommended to administer a regimen of antibiotics (AB) and antiseizure medication (ASM) during the first week after pTBI, as well as to administer anti-pneumococcal and anti-tetanus vaccination [6–18]. The duration of AB prophylaxis is debated, however in a recent systematic review the authors recommend a short course of AB without clearly defining the duration [19]. Complications after cpTBI are numerous and include vessel injury, infection, cerebrospinal fluid leak, epilepsy, neurological sequels and death [20–24]. Given the substantial complexity associated with pTBI, we acknowledge and strongly support the work of the BTF and the recent publication of the second edition of the pTBI guidelines [25]. In effect, the surgical repair and intensive care management of cpTBI is complex. Since cpTBI usually causes injury to the brain parenchyma, many patients experience substantial neurological compromise and high mortality risk. Treatment therefore aims to prevent secondary insults, decrease the risk of infection and early seizures, and restore the anatomical integrity of intracranial structures through meticulous debridement and dural repair. Despite existing recommendations, compliance with guideline-based management may be variable due to the rarity of cpTBI and limited familiarity among clinicians. Furthermore, concerns have been raised regarding the lack of guideline updating for pTBI, particularly for injuries among civilians [26]. Much of the literature on penetrating TBI derives from the military setting, conflict zones or from studies on high-energy weapons [27–29]. Civilian data are therefore necessary to support future updates to pTBI guidelines, identify gaps in current practice, and refine evidence-based recommendations. Against this background, we conducted a study of patients with cpTBI managed at the tertiary trauma centre in South-East Norway. The study aims were threefold: (1) to describe the epidemiology of cpTBI in a defined Norwegian population, (2) to assess adherence to pTBI guidelines including CTA, prophylactic AB and ASM, as well as surgical debridement and ICP monitoring; and (3) calculate the 30-day mortality and outcome for patients surviving the first 30 days. Material and methods Patients and treatment The neurosurgical department at Oslo University Hospital (OUH) is the only provider of neurosurgical care in the southeastern region of Norway, where the population increased from 2.9 to 3.1 million in the study period. The region has 19 local hospitals that refer and consult TBI patients with the tertiary trauma centre (OUH). In 2015, the Oslo TBI Registry – Neurosurgery (OTBIR-N) was established. This is a prospective quality control database maintained by the neurosurgical department. We register patients consecutively, and clinical data are retrieved manually from electronic medical records and stored in a Medinsight database [30]. The inclusion criteria for this registry are: (1) traumatic brain injury, (2) Image verified acute trauma (haemorrhage, fracture, traumatic axonal injury, vascular injury), (3) admission to OUH within seven days of injury, (4) a Norwegian social security number. We included patients registered in the period Jan 1, 2015, to Dec 31, 2023. Guidelines for cpTBI management at OUH In general, neurosurgical triage, evaluation and treatment follows the Brain Trauma Foundation Guidelines and local protocols [5, 8]. Regarding cpTBI the management is based on the recommendations from the 2001 BTF Guidelines for the management of pTBI [2], as well as recommendations from the UpToDate online reference [3]. In this study, we defined cpTBI as a radiographically verified penetration of any object through the skull with entry into the intracranial space. For cpTBI the hospital management protocol includes CTA of pre-and intracerebral vessels, prophylactic AB, and ASM for ≥ 7 days after injury [8–11, 13, 14]. In line with a recent systematic review recommending shorter courses of AB, we defined adequate AB as ≥ 3 days with 3rd generation cephalosporin+vancomycin, or meropenem+vancomycin for patients with penicillin allergy [19]. Incomplete AB was defined as duration ≥ 3 days but with cephalosporin, meropenem or vancomycin monotherapy. Inadequate regimen was defined as shorter than 3 days or none of the above AB. Tetanus vaccination is administered broadly according to standard trauma prophylaxis practices. Pneumococcal vaccination is primarily reserved for patients who have undergone splenectomy, in accordance with established immunization guidelines for asplenic individuals. ASM therapy is administered in agreement with the neurologist on-call; in the study we defined ≥ 7 days prophylaxis with either phenytoin, levetiracetam or valproic acid as adequate ASM. Shorter courses or alternative agents were categorized as non-adherent to recommended prophylaxis. The hospital routine is surgical debridement, revision and dural closure as soon as possible. The indication for ICP monitoring of cpTBI patients is GCS < 9 [5, 8]. Treatment limiting decision (TLD) After initial triage at the trauma centre, depending on the clinical state of the patient and/or the results of neuroimaging, the neurosurgical team may declare a treatment limiting decision (TLD) if the prognosis is dismal and not in line with meaningful survival. The TLD prevents overtreatment and a prolonged course of treatment without effect on an ultimately grave prognosis [31]. If the neurosurgical team is uncertain of the prognosis, regular treatment is started in line with the BTF guidelines and re-evaluated daily. This dynamic reassessment allows time for neurological evolution while avoiding premature withdrawal of potentially beneficial therapy. Variables From the registry and charts we retrieved the following data: injury mechanism and object causing cpTBI, bullet calibre, CT head: visible projectile, penetration of midline, TLD, type and duration of AB, type and duration of ASM, age, sex, preinjury American Society of Anesthesiologists Physical Status Classification system (ASA) [32], pupillary status, lowest registered GCS, multitrauma, head injury severity scale (HISS) [33] divided into complicated mild; moderate; severe, Rotterdam CT score [34], timing and type of surgery, ICP monitoring, tracheostomy, discharge date, days in ICU, days on ventilator, death date, Glasgow outcome scale (GOS) [35] and date of injury. We dichotomized outcome into favourable (GOS 4 and 5) and unfavourable (GOS 1–3). Outcome measures included mortality, which is automatically updated in the registry through linkage with the national population registry, and functional outcome assessed using the Glasgow Outcome Scale (GOS). GOS was determined at 6 months post-injury based on information available in electronic patient records, including reports from rehabilitation institutions or local hospitals, and/or scheduled phone-based follow-up conducted by the neurosurgical department at OUH. We defined acceptable guideline compliance as follows: >80% managed with CTA, adequate prophylactic AB and ASM; >80% of operations starting < 12 h after injury; >80% ICP monitoring of patients with GCS < 9. Statistics For statistical analyses we used IBM SPSS Statistics version 29, Stata (StataCorp. 2023. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC.). A p-value of < 0.05 was considered significant for two-sided hypotheses, and we did not adjust for multiple comparisons. Data are presented as frequencies for categorical data and median and /or mean values for continuous data. The chi square test was used for categorical variables and a t test or Mann Whitney U test for skewed continuous data, as appropriate. We performed two multiple logistic regression analyses to assess the relationship between (1) early death and (2) unfavourable outcome, respectively, and radiographic evidence of injury violating the intracranial midline and gunshot injury, controlling for age. Collinearity was assessed using pairwise correlation analysis, which demonstrated minimal correlation between midline violation and gunshot injury (r = 0.21), indicating no meaningful multicollinearity requiring variable exclusion. Ethics The OUH data protection officer approved the Medinsight database (approval number 2016/17569) and approved the study as a quality control study (approval number 24/24031). Artificial intelligence (AI) The authors generated the text, figures and tables with no use of AI. Upon final language editing, individual sections of the manuscripts were uploaded into Microsoft Copilot with the following prompt: “suggest improvements for better readability, mark improvements in italics, keep all content”. We then either rejected or accepted suggestions that we found to improve the overall readability. This approach ensured full author control over the scientific content while allowing targeted refinement of language and clarity. Results Epidemiology In total, we identified 52 patients with cpTBI in the study period. The annual case load was low (median 5, IQR 3–7), resulting in a crude incidence rate of 1.9/1.000.000 cpTBI patients presenting alive to the trauma centre in the OUS catchment area. The median age was 38 years (IQR 22–59), 94% were male, and 40.4% had moderate or severe preinjury disease. The most common penetrating mechanism was gunshot injuries, identified in 55.8% of the patients. The most frequent bullet calibre was 9 mm (27.6%). The main triggering factor of cpTBI was self-inflicted injury (59.6%), followed by violence (23.1%) and accidents (17.3%). The median GCS recorded before admission was 6.5 (IQR 3–14) and the median Rotterdam CT score on admission was 3 (IQR 2–5). Multitrauma was present in 31/52 (59.6%). Treatment limiting decision In 21 patients (40%), a TLD was made shortly after admission. Of these, 19 patients had gunshot injuries. At day 1 after injury 57% of the TLD patients were dead, and 100% were dead by day five. Guideline compliance The fraction of patients triaged with CTA was 81%, wherein vessel injury was found in 20 patients (48% of CTAs). In addition to CTA, digital subtraction angiography (DSA) was performed in three patients. Altogether, three patients underwent endovascular treatment. None required craniotomy with open vascular repair. Delayed vascular injury was identified in one patient on DSA performed on day 10 post‑injury. Repeat CTA was obtained in eight patients. Low‑molecular‑weight heparin was administered in eight patients with vascular injuries. Only 12% of the patients received an adequate AB regimen (Fig. 1a). We found that 29% received adequate ASM prophylaxis according to recommendations (Fig. 1b). Open surgery (excluding external ventricular drain and ICP monitor) was performed in 26 patients (50%), where surgery started within 12 h after injury in 58%. ICP was monitored in 15 of 28 (53.5%) cpTBI patients with GCS < 9. According to HISS 13 of 28 (46.4%) patients with severe injuries did not receive ICP monitoring. ICP monitoring was introduced in 8 patients subsequently receiving a TLD. Fig. 1Guideline compliance with prophylactic antibiotics (a) and antiseizure medication (b) after cpTBI. Green=adequate, orange=incomplete=orange, red=inadequate, grey=none Guideline compliance with prophylactic antibiotics (a) and antiseizure medication (b) after cpTBI. Green=adequate, orange=incomplete=orange, red=inadequate, grey=none 30-day mortality and outcome Within 30 days after cpTBI 22 patients (42.3%) were dead, of whom 19 patients (86%) had gunshot injuries. Patients dying early had significantly higher Rotterdam CT score, more frequently abnormal pupils, gunshot injuries, and lower GCS (Table 1). Table 1Demographic, clinical and injury characteristics of cpTBI patientsVariableSurvived > 30 daysDead within 30 daysP ValueN (%)30 (58)22 (42)Age years, median (IQR)37 (23–49)45 (22–67)0.2Male sex, n (%)29 (97)20 (91)0.77ASA performance status – healthy, n (%)20 (67)11 (50)0.2Gunshot, n (%)10 (33)19 (86)< 0.001Any pupil abnormality, n (%)3 (10)11 (50)0.001HISS moderate and severe, n (%)14 (47)21 (95)< 0.001Midline violation on CT, n (%)7(23)15 (68)0.001Visible foreign object on CT, n (%)20 (67)19 (86)0.1Rotterdam CT score 5 and 6, n (%)1 (3)17 (77)< 0.001Multiple trauma, n (%)21 (70)10 (45)0.075Treatment limiting decision0 (0)21 (95)< 0.001 Table 1Demographic, clinical and injury characteristics of cpTBI patientsVariableSurvived > 30 daysDead within 30 daysP ValueN (%)30 (58)22 (42)Age years, median (IQR)37 (23–49)45 (22–67)0.2Male sex, n (%)29 (97)20 (91)0.77ASA performance status – healthy, n (%)20 (67)11 (50)0.2Gunshot, n (%)10 (33)19 (86)< 0.001Any pupil abnormality, n (%)3 (10)11 (50)0.001HISS moderate and severe, n (%)14 (47)21 (95)< 0.001Midline violation on CT, n (%)7(23)15 (68)0.001Visible foreign object on CT, n (%)20 (67)19 (86)0.1Rotterdam CT score 5 and 6, n (%)1 (3)17 (77)< 0.001Multiple trauma, n (%)21 (70)10 (45)0.075Treatment limiting decision0 (0)21 (95)< 0.001 Demographic, clinical and injury characteristics of cpTBI patients For the total cohort, death (GOS 1) occurred in 24 of 52 (46%) cpTBI patients. Time from injury to death was median 1.5 days (IQR 1–4 days). The clinically important factors injury violating the intracranial midline on CT imaging and gunshot injury were associated with 30-day mortality (Table 2). Table 2Prediction of 30-day mortality and unfavourable outcomeVariables30-day mortalityUnfavourable outcomeOR (95%CI)P valueOR (95%CI)P valueAge1.0 (0.9-1.1)0.31.0 (0.9–1.1)0.1Midline violation10.4 (1.9–55)0.00613.6 (2.5–73)0.002Gunshot vs. other penetration11.8 (2.2–63)0.0046.7 (1.4–32)0.016 Table 2Prediction of 30-day mortality and unfavourable outcomeVariables30-day mortalityUnfavourable outcomeOR (95%CI)P valueOR (95%CI)P valueAge1.0 (0.9-1.1)0.31.0 (0.9–1.1)0.1Midline violation10.4 (1.9–55)0.00613.6 (2.5–73)0.002Gunshot vs. other penetration11.8 (2.2–63)0.0046.7 (1.4–32)0.016 Prediction of 30-day mortality and unfavourable outcome For the entire cohort, the median GOS at 6 months was 3 (IQR 1–4). We found that 30 patients (58%) survived longer than 30 days after pTBI. On follow-up the GOS for survivors was median 4.0 (IQR 4–5). For patients surviving longer than 30 days after injury, a favourable outcome (GOS 4 and 5) occurred in 21 (70%). Only two (4%) patients died later than 30 days after injury. None of the survivors were in persistent vegetative state. Outcome data on follow-up was missing for 1 patient. Injuries violating the intracranial midline and gunshots were associated with unfavourable outcome (Table 2). Discussion In this study on cpTBI patients admitted to the tertiary trauma centre in Oslo, Norway, we found an incidence of 1.9/1.000.000 where 94% were male. The 30-day mortality rate was 42.3%; however, among survivors the majority had functional independence at 6 months follow-up (median GOS 4). Triage with CTA demonstrated acceptable adherence to recommendations, with imaging obtained in 81% of the cases. In contrast, adherence to prophylactic AB and ASM guidelines was markedly lower than anticipated, at 12% and 29%, respectively. Revision surgery commenced within 12 h after injury in 58%, and ICP monitoring was implemented in 54% of patients presenting with a GCS < 9. Consequently, we have identified several key components to improve cpTBI management in Norway’s largest trauma centre. Neurovascular imaging In our study, we found that 81% of the total cohort underwent CTA screening in the acute phase, which indicates a high degree of guideline compliance. Only three patients were examined with DSA, and three patients needed endovascular vessel repair. In our hospital, a verified traumatic intracranial arterial injury is managed either surgically, endovascularly or medically depending on the imaging results, and DSA is performed after consultation with neurovascular interventionists. If only medical treatment is necessary, treatment with low- molecular-weight heparin (50–100 IU/kg x 2 daily) is started early, with subsequent transfer to acetylsalicylic acid 75 mg x1 daily when this is considered safe and feasible [36]. In the current study, we did not intend to investigate the panorama of injured vessels or to determine which treatment was required. However, the study clearly supports CTA in cpTBI patients because injury to pre- or intracerebral arteries was found in as many as 20 patients (38% of all patients). In the updated edition of the BTF pTBI guidelines, the assessment and monitoring of potential vascular injury have been substantially revised [25]. DSA is now recommended in cases of suspected vasospasm, when CTA is insufficient to exclude vascular injury, and when CTA has already confirmed such an injury. In addition, the guidelines advise repeat vascular imaging between 7 and 21 days following injury, or prior to hospital discharge, to detect delayed vascular complications. These changes necessitate an adjustment to our current treatment protocol, which can no longer rely primarily on CTA. Antibiotics Regarding prophylactic AB, we found a nihilistic approach and a high proportion of incomplete, inappropriate or no treatment, where only 12% received an adequate AB regimen. Generally, prophylactic treatment with vancomycin plus cefepime; or vancomycin plus ceftazidime; or vancomycin plus meropenem after pTBI is recommended [13, 14]. The duration of antibiotics after pTBI has not been evaluated in RCTs, however a minimum duration for 5–7 days is recommended by some authors [6, 13, 14]. Due to the lack of consensus, we used a conservative definition of adequate AB duration (≥ 3 days). This approach aimed to establish a pragmatic threshold that could be evaluated consistently across patients. The highly variable practice in the study could be related to weak guideline implementation or doubt about which regimen that should be offered. Such uncertainty is likely amplified by the rarity of cpTBI and the limited evidence base supporting specific prophylactic strategies. In our opinion, all patients not receiving a TLD shortly after admission, should be offered an adequate course of prophylactic AB. In the recently updated BTF guidelines for treatment of pTBI there is level III evidence supporting that prophylactic AB can be considered [25]. In the Delphi voting there was consensus for giving AB as soon as possible with broad-spectrum agents and for 5 days in higher risk cases and 3 days when there is lower risk. Antiseizure medication The rate of adequate prophylactic treatment with ASM was lower than expected, where as many as 71.2% did not receive ASM for the recommended 7 days after pTBI. Due to the retrospective study design, we had no intention to calculate the risk of seizures after cpTBI. However, in a recent study from our hospital including 1827 TBI patients new-onset seizures within the first week occurred in 5.6% overall [37]. Although this estimate is not specific to penetrating injuries, it highlights that early post-traumatic seizures are a clinically relevant complication [9–11]. Seizure prophylaxis as mentioned above is supported by the updated version of the BTF guidelines for the management of pTBI [25]; however, it is important to recognize that the recommendation is only supported by expert consensus. Thus, while prophylaxis is widely practiced, the underlying evidence base remains limited. The choice of ASM may be discussed with the neurologist on-call, however in most cases levetiracetam or valproic acid are appropriate choices. Both agents are commonly used in acute neurotrauma due to favourable safety profiles, rapid titration, and widespread clinician familiarity. ICP monitoring and surgical revision In our department, neuromonitoring with intraparenchymal ICP sensors is available 24/7, and the ICP treatment protocol follows the BTF guidelines. Target measures for adults are CPP > 60 mmHg and ICP < 22 mmHg, with the MAP zero-level at the tragus. According to the HISS grading of the cpTBI patients we made some conflicting observations. First, there were 28 severely injured patients according to HISS. In agreement with the BTF, ICP monitoring is indicated for all these patients. However, we found a less than satisfactory guideline compliance where only 15 (53.5%) of these were monitored. This indicates inconsistent implementation of monitoring recommendations in a group at high risk for intracranial hypertension. Furthermore, 8 patients that received a TLD were ICP monitored, contradicting the ultimately pessimistic prognosis. The reason for variable ICP monitoring practice in these cases remains unclear; however, we speculate that the initial clinical situation may have caused management uncertainty. Available guidelines suggest that revision surgery with closure of dural defects should commence as soon as possible after injury. Moreover, the new BTF guidelines recommend that surgery should start within 5 h after injury [25]. In our study, surgical revision was offered to 50% of all patients, which raises the suspicion that the indications have been too strict. This finding may reflect cautious surgical decision-making in borderline cases or uncertainty in assessing salvageability. Furthermore, we found that only 58% of surgical candidates reached the study goal of surgery within 12 h after injury. The study was not designed to assess potential risk of delayed surgery; however, the data demonstrates room for improvement and the possibility of implementing a faster track into the operating room for cpTBI. Streamlining pathways for urgent surgical debridement and dural repair may therefore be a key quality‑improvement target. 30-day mortality and outcome For patients surviving more than 30 days after cpTBI, 70% had favourable outcome. For patients dying within 30 days, 95% occurred by day five. All of these had received a TLD. In line with clinical experience, we found that injuries crossing the intracranial midline and gunshots both were associated with both early death and unfavourable outcome. These findings support the notion that such radiographic and mechanistic indicators can aid clinicians in early prognostication. The presence of these factors could facilitate clinicians in making a TLD in the early phase after cpTBI. Our study shows unnecessary variability and low guideline compliance in the management of cpTBI. It has been documented that adherence to guidelines is lower-than-expected in American TBI patients and [38, 39], and that mortality after severe TBI improves with increasing adherence for guidelines [40]. These external findings strengthen the concern that suboptimal adherence may negatively affect outcomes and reinforces the need for consistent protocol implementation. We speculate that the low compliance may be caused by outdated guidelines and a low annual volume of cpTBI patients. With the new edition of the BTF guidelines on pTBI we hope that clinical decisions and ultimately patient care will improve. For cpTBI patients we support adequate neuromonitoring and ICP tailored treatment according to established thresholds, early debridement and dural closure as soon as possible and within the recommended 5 h [25] after injury, as well as giving prophylactic AB and ASM. These measures may help reduce secondary injury, stabilize physiological parameters and improve functional recovery in this highly vulnerable patient population. Limitations and strengths This study has several limitations. First, the data were collected at a single centre and therefore reflect local treatment protocols and adherence patterns, which may limit external validity. Second, the number of patients with cpTBI was relatively small. In addition, the retrospective study design carries an inherent risk of selection and information bias. Together, these factors restrict the generalizability of the findings, and confirmation in other cpTBI populations is warranted. Future multicentre collaborations may help overcome these limitations. The limited sample size also constrained the statistical analyses. Multivariable logistic regression could only include a small number of covariates, and analyses were therefore restricted to midline violation and gunshot injury, adjusted for age. Although statistically significant associations were identified, the wide confidence intervals reflect the low number of observations. Consequently, the results should be interpreted as indicating an increased risk associated with these factors rather than providing precise estimates of effect size. Caution is therefore needed when extrapolating these estimates to broader populations. Despite these limitations, the study has important strengths. Our institution is the sole neurosurgical referral centre for the defined catchment area, making it likely that all patients with cpTBI who survived long enough to reach hospital were captured. Thus, the reported incidence most likely represents the true real-world burden of cpTBI presenting to the trauma centre in this region. Given the very low incidence of civilian pTBI, management practices may vary considerably between trauma centres with similar caseloads. In this context, we believe that our findings provide clinically relevant insights and may be of value to clinicians managing cpTBI in comparable settings. These data may also help inform upcoming guideline revisions and local quality‑improvement initiatives. Conclusion The incidence of cpTBI in our catchment area was 1.9/1.000.000. We found a lower-than-expected guideline compliance for AB, ASM, ICP monitoring and early surgical revision. For CTA we found adequate compliance. Thirty-day mortality after cpTBI was 42%, while 70% of survivors achieved a favourable outcome. Intracranial injury crossing the midline and gunshot mechanism were strong predictors of early mortality and unfavourable outcome. These factors may therefore serve as important indicators during early prognostic assessment. Because 70% of survivors had functional independence at 6 months, our study supports that for patients considered potential survivors, management should be aggressive and aligned with established TBI treatment principles. This includes early vascular imaging with CTA, prompt wound debridement with dural closure, and prophylactic administration of AB and ASM. Adhering to these principles may help reduce secondary injury and improve long‑term functional recovery in this highly vulnerable patient group.